Pharmafile Logo

Nanobiotix announces that Bpifrance has awarded the company an interest free loan

September 19, 2016 – Pharmaceutical –

Paris, France, and Cambridge, Massachusetts, USA, September 19, 2016 – NANOBIOTIX (Euronext:
NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company
pioneering novel approaches for the local treatment of cancer, announced
today that Bpifrance has awarded the Company an interest-free loan of
Ä2M for Innovation (prÍt ‡ taux zÈro pour líInnovation – PTZI).

The
interest-free loan, repayable from September 2019, aims to support the
development of Nanobiotixís lead product, NBTXR3, which is currently
under registration trial (Phase II/III) with Soft Tissue Sarcoma.
Nanobiotix has recently filed for a CE Mark for the product.

A nanomedicine product in registration phase

NBTXR3
is a first-in-class radio-enhancer based on the NanoXray technology,
designed for direct injection into cancerous tumors. The product is
engineered to increase the dose and efficacy of radiotherapy without
increasing toxicity or causing damage to surrounding healthy tissues.

NBTXR3
is currently in clinical development in six indications: Soft Tissue
Sarcoma, Head and Neck cancers, Prostate, Liver cancers (primary and
metastases) and rectal (via PharmaEngine, partner for the Asia Pacific
area). Philippe Mauberna, CFO of Nanobiotix, commented: ‘Bpifrance
has shown Nanobiotix a continual high level of support since our
inception for which we are very pleased. This interest-free loan will
contribute to financing the last steps of the NBTXR3 registration study
in Soft Tissue Sarcoma. This is an exciting period for the Company.’



Bpifrance, a historic partner of the Company

Bpifrance
(ex OSEO), has supported Nanobiotixís dynamic development for over 12
years. This support has taken a number of forms such as repayable grants
or inclusion in Strategic Industrial Innovation (ISI) programs, such as
the ‘NICE project’, a collaborative project dedicated to liver cancers
and managed by Bpifrance.

Eric Tossah, Bpifrance, commented: “The
Bpifrance team is delighted to put this new loan together for
Nanobiotix which demonstrates our deep support and confidence in this
innovative French technology. Nanobiotix is rapidly growing with an
international and renowned management team. They launched an affiliate
in the Boston area two years ago, and have welcomed a number of North
American life sciences specialist investors.”

Nanobiotix
NGIN, 210 Broadway Cambridge, MA02139, US